NSC 651016

Drug Profile

NSC 651016

Latest Information Update: 30 Apr 2002

Price : $50

At a glance

  • Originator Nonindustrial sources
  • Class Antivirals; Naphthalenesulfonates
  • Mechanism of Action Chemokine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Graft-versus-host disease; HIV infections

Most Recent Events

  • 01 May 2000 An in vitro study has been added to the pharmacodynamis section of transplant rejection (816659
  • 01 May 2000 Preclinical development for Graft-versus-host disease in USA (Parenteral)
  • 15 Oct 1998 Preclinical development for HIV infections prevention in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top